Your browser is no longer supported. Please, upgrade your browser.
Settings
RYTM Rhythm Pharmaceuticals, Inc. daily Stock Chart
RYTM [NASD]
Rhythm Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-2.61 Insider Own1.60% Shs Outstand34.23M Perf Week-3.20%
Market Cap889.98M Forward P/E- EPS next Y-3.39 Insider Trans- Shs Float30.56M Perf Month1.96%
Income-86.60M PEG- EPS next Q-0.86 Inst Own91.00% Short Float4.54% Perf Quarter-11.26%
Sales- P/S- EPS this Y15.70% Inst Trans-2.58% Short Ratio15.36 Perf Half Y-4.48%
Book/sh6.41 P/B4.06 EPS next Y1.50% ROA-32.50% Target Price38.33 Perf Year-14.47%
Cash/sh6.47 P/C4.02 EPS next 5Y34.60% ROE-33.90% 52W Range23.44 - 37.23 Perf YTD-3.27%
Dividend- P/FCF- EPS past 5Y-38.10% ROI- 52W High-30.16% Beta-
Dividend %- Quick Ratio18.30 Sales past 5Y- Gross Margin- 52W Low10.92% ATR1.36
Employees54 Current Ratio18.30 Sales Q/Q- Oper. Margin- RSI (14)45.43 Volatility6.23% 4.76%
OptionableYes Debt/Eq0.00 EPS Q/Q-39.60% Profit Margin- Rel Volume1.10 Prev Close26.51
ShortableYes LT Debt/Eq0.00 EarningsJun 07 BMO Payout- Avg Volume90.31K Price26.00
Recom1.80 SMA20-0.27% SMA50-4.60% SMA200-8.37% Volume99,646 Change-1.92%
Mar-13-19Initiated Ladenburg Thalmann Buy $43
Sep-07-18Resumed Morgan Stanley Overweight
Jun-25-18Reiterated Needham Buy $36 → $42
Jun-15-18Reiterated Needham Buy $32 → $36
Oct-30-17Initiated Needham Buy $32
Oct-30-17Initiated BofA/Merrill Buy $30
May-07-19 10:54AM  Heres What Hedge Funds Think About Rhythm Pharmaceuticals, Inc. (RYTM) Insider Monkey
08:00AM  Rhythm Pharmaceuticals to Present at Bank of America Merrill Lynch 2019 Health Care Conference GlobeNewswire
May-03-19 08:36AM  Rhythm Pharmaceuticals Reports First Quarter 2019 Financial Results GlobeNewswire
Apr-26-19 12:13PM  If You Had Bought Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock A Year Ago, You Could Pocket A 10% Gain Today Simply Wall St.
Apr-02-19 08:00AM  Rhythm Pharmaceuticals to Present at 18th Annual Needham Healthcare Conference GlobeNewswire
Apr-01-19 08:00AM  Medison to Nominate Six Highly Qualified Directors for Knight Therapeutics' Board to Strengthen Oversight and Drive Value Creation for All Shareholders CNW Group
Mar-28-19 07:00AM  Rhythm Pharmaceuticals Announces Promising Clinical Data in MC4R Pathway Heterozygous Obesity and Strategy for Further Development GlobeNewswire
Mar-08-19 08:12AM  Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results GlobeNewswire
Mar-04-19 08:00AM  Rhythm Pharmaceuticals to Present at Cowen & Co. 39th Annual Health Care Conference GlobeNewswire
Feb-07-19 07:55AM  Recent Analysis Shows Alexion Pharmaceuticals, Plug Power, Rayonier Advanced Materials, SunCoke Energy, Rhythm Pharmaceuticals, and Armstrong Flooring Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Jan-25-19 11:03AM  A Look At The Fair Value Of Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Simply Wall St.
Jan-04-19 08:00AM  Rhythm Pharmaceuticals to Outline Expected 2019 Milestones and Review Updated Clinical Data in Bardet-Biedl Syndrome at 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire +7.59%
Dec-13-18 07:00AM  Rhythm Pharmaceuticals Announces First Patient Enrolled in Pivotal Phase 3 Clinical Trial Evaluating Setmelanotide in Bardet-Biedl and Alström Syndromes GlobeNewswire
Dec-06-18 08:00AM  Rhythm Pharmaceuticals to Host Key Opinion Leader Symposium on MC4R Pathway and Patient Experience with Rare Genetic Disorders of Obesity, Including Bardet-Biedl Syndrome GlobeNewswire
Nov-15-18 08:00AM  Rhythm Pharmaceuticals Announces Presentation of Updated Clinical Data from Phase 2 Basket Studies Evaluating Setmelanotide in Alström Syndrome at ObesityWeek 2018 GlobeNewswire
Nov-09-18 08:00AM  Rhythm Pharmaceuticals Reports Third Quarter 2018 Financial Results GlobeNewswire -6.35%
Nov-07-18 08:00AM  Rhythm Pharmaceuticals to Present at Stifel 2018 Healthcare Conference GlobeNewswire
Oct-17-18 08:15AM  Report: Exploring Fundamental Drivers Behind CURO Group, BiondVax Pharmaceuticals, AMAG Pharmaceuticals, AcelRx Pharmaceuticals, Ballard Power, and Rhythm Pharmaceuticals New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Oct-15-18 08:00AM  Rhythm Pharmaceuticals Appoints Murray W. Stewart, M.D., as Chief Medical Officer GlobeNewswire
Sep-28-18 07:00AM  Rhythm Pharmaceuticals Announces Presentation of Updated Clinical Data from Phase 2 Basket Studies Evaluating Setmelanotide in Bardet-Biedl Syndrome and Alström Syndrome at 57th Annual ESPE Meeting GlobeNewswire
07:00AM  Rhythm Pharmaceuticals Announces Launch of TEMPO Registry for Rare Genetic Disorders of Obesity GlobeNewswire
Sep-25-18 08:00AM  Rhythm Pharmaceuticals to Present at Ladenburg Thalmann 2018 Healthcare Conference GlobeNewswire -15.66%
Sep-16-18 04:31PM  The Smartest People on Wall Street Are Buying These 3 Stocks. Should You Follow? Motley Fool
Sep-07-18 08:00AM  Rhythm Pharmaceuticals to Present at Morgan Stanley 16th Annual Global Healthcare Conference GlobeNewswire
Aug-20-18 07:55AM  New Research: Key Drivers of Growth for Harmonic, Astec Industries, Marlin Business Services, Arsanis, SunOpta, and Rhythm Pharmaceuticals Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Aug-08-18 04:01PM  Rhythm Pharmaceuticals Reports Second Quarter 2018 Financial Results GlobeNewswire
Jul-23-18 08:00AM  Rhythm Pharmaceuticals Receives European Medicines Agency PRIME Designation for Setmelanotide in Rare Genetic Disorders of Obesity GlobeNewswire
Jun-25-18 04:01PM  Rhythm Pharmaceuticals, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters Option to Purchase Additional Shares GlobeNewswire
Jun-21-18 03:31PM  Here's Why Rhythm Pharmaceuticals Inc Rose as Much as 37% Today Motley Fool +24.56%
Jun-20-18 09:37PM  Rhythm Pharmaceuticals, Inc. Announces Pricing of Public Offering GlobeNewswire
Jun-18-18 05:19PM  Rhythm Pharmaceuticals, Inc. Announces Proposed Public Offering GlobeNewswire -11.66%
07:00AM  Rhythm Pharmaceuticals Announces New Topline Clinical Data from Ongoing Phase 2 Basket Studies Evaluating Setmelanotide in Rare Genetic Disorders of Obesity GlobeNewswire
Jun-14-18 08:00AM  Rhythm Pharmaceuticals Completes Pivotal Enrollment in Two Ongoing Phase 3 Clinical Trials Evaluating Setmelanotide in Rare Genetic Disorders of Obesity GlobeNewswire
Jun-05-18 07:45AM  Factors of Influence in 2018, Key Indicators and Opportunity within BiondVax Pharmaceuticals, MercadoLibre, 1-800 FLOWERS.COM, Redhill Biopharma, Mountain Province Diamonds, and Rhythm Pharmaceuticals New Research Emphasizes Economic Growth GlobeNewswire
Jun-04-18 09:41AM  The Zacks Analyst Blog Highlights: Illumina, Athersys, EyePoint Pharmaceuticals, Rhythm Pharmaceuticals and Ligand Pharmaceuticals Zacks
Jun-01-18 08:00AM  Rhythm Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference GlobeNewswire
May-31-18 06:45AM  Will Rhythm Pharmaceuticals (RYTM) Continue to Surge Higher? Zacks
May-14-18 08:00AM  Rhythm Pharmaceuticals Reports First Quarter 2018 Financial Results GlobeNewswire +12.83%
May-09-18 04:01PM  Rhythm Pharmaceuticals to Present at the Bank of America Merrill Lynch 2018 Health Care Conference GlobeNewswire
04:01PM  Rhythm Pharmaceuticals Announces Nature Medicine Publication of Longer-Term Data from Phase 2 Study of Setmelanotide for Treatment of LEPR Deficiency Obesity GlobeNewswire
Apr-11-18 07:40AM  Consolidated Research: 2018 Summary Expectations for Ctrip.com International, JA Solar Holdings, Co., Oaktree Specialty Lending, Rhythm Pharmaceuticals, Cellectis S.A, and Travelport Worldwide Fundamental Analysis, Key Performance Indications GlobeNewswire
Apr-02-18 08:00AM  Rhythm Pharmaceuticals Announces Licensing Agreement with Takeda for the Development and Commercialization of Preclinical Treatment for Prader-Willi Syndrome GlobeNewswire -14.47%
Mar-19-18 04:01PM  Rhythm Pharmaceuticals Announces Presentation of Genetic Epidemiology of LEPR, POMC, And PCSK1 Variants at ENDO 2018 GlobeNewswire
Mar-15-18 08:15AM  Report: Exploring Fundamental Drivers Behind Reading International, Rhythm Pharmaceuticals, Grupo Aeroportuario del Centro Norte S.A.B. de C.V., Golar LNG, Central European Media Enterprises, and MediciNova New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire -10.89%
Mar-12-18 04:01PM  Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results GlobeNewswire
Mar-07-18 04:01PM  Rhythm Pharmaceuticals to Present at Upcoming Investor Conferences in March GlobeNewswire
Jan-09-18 09:00AM  WuXi NextCODE Artificial Intelligence Used to Advance Precision Therapy for Rare Genetic Disorders of Obesity PR Newswire -5.53%
Jan-04-18 08:00AM  Rhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity GlobeNewswire
Nov-14-17 08:00AM  Rhythm Pharmaceuticals Reports Third Quarter 2017 Financial Results GlobeNewswire -5.66%
07:00AM  Torque, a Flagship Pioneering Company, Launches Platform to Develop a New Class of Deep-Primed Immune Cell Therapies, Financed with $25M Series A and Led by a Veteran Management Team PR Newswire
Nov-13-17 10:00AM  Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM) to Ring The Nasdaq Stock Market Closing Bell GlobeNewswire +5.16%
Nov-02-17 07:20AM  Two Boston-area biotechs raise combined $152M in IPOs American City Business Journals -7.70%
Oct-31-17 08:01AM  Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome GlobeNewswire
Oct-10-17 04:13PM  This Company Gained 76% in its IPO -- and It Isn't Even a Tech Company Motley Fool +5.86%
04:01PM  Rhythm Pharmaceuticals, Inc. Announces Closing of Initial Public Offering and Full Exercise of Underwriters Option to Purchase Additional Shares GlobeNewswire
Oct-08-17 08:41AM  IPO News This Week: Online Auto Marketplace, CarGurus, Tops the List 24/7 Wall St.
Oct-06-17 11:45AM  Switch Keeps Recent IPO Market Momentum Going Benzinga -15.83%
Oct-04-17 09:09PM  Rhythm Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering GlobeNewswire
Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alstrom syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders. It is also developing RM-853, an orally available ghrelin o-acyltransferase inhibitor that is in preclinical development for Prader-Willi syndrome. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.